Compare FNWB & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | PMVP |
|---|---|---|
| Founded | 1923 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 79.5M |
| IPO Year | 2012 | 2020 |
| Metric | FNWB | PMVP |
|---|---|---|
| Price | $9.08 | $1.33 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 34.5K | ★ 455.5K |
| Earning Date | 04-23-2026 | 03-06-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.82 |
| 52 Week High | $10.98 | $1.88 |
| Indicator | FNWB | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 47.07 |
| Support Level | $7.56 | $1.26 |
| Resistance Level | $9.00 | $1.39 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 67.28 | 34.62 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.